Pilots, Truck Drivers, and Compounded GLP-1s: FAA and FMCSA Rules

FAA guidance for aviation medical examiners accepts a single GLP-1 medication for weight loss under specific conditions, but it names brand products and says nothing about compounded versions, so it neither approves nor rejects compounded semaglutide or tirzepatide. For commercial truck and bus drivers, federal FMCSA rules do not single out GLP-1s; the diabetes standard addresses insulin-treated diabetes. In both cases, the safest assumption is that you disclose everything and treat any change in your compounded product as a change your examiner should know about.

What the FAA guidance actually says

The FAA's Weight Loss Pharmaceuticals document in the Guide for Aviation Medical Examiners, revised 08/26/2026, sorts weight-loss drugs into acceptable, conditionally acceptable, and unacceptable groups.

• Acceptable: orlistat; or a single diabetic-class component, such as metformin or a GLP-1 agonist. The document gives liraglutide, semaglutide (Wegovy, "injection or oral"), and tirzepatide (Zepbound) as examples. Orlistat plus one GLP-1 is also acceptable.
• Conditionally acceptable (Special Issuance required): two diabetic-class components together, such as metformin plus a GLP-1.
• Unacceptable: drugs including phentermine, phentermine with topiramate (Qsymia), and bupropion with naltrexone (Contrave), alone or in combination.

For the acceptable GLP-1 path, the A1C must be 6.4 or less, with no diabetes diagnosis and no history of hypoglycemia requiring intervention. If the medication is used for diabetes rather than weight loss, the document sends examiners to FAA's diabetes guidance instead.

The observation periods

The same document sets a one-week observation period after starting a single diabetic-component medication for weight loss, and a 48-hour observation after "each dose increase, medication change, or formulation change." It also reminds pilots that symptoms that may interfere with flight duties, regardless of treatment, mean they must not fly under 14 CFR 61.53.

The examiner's worksheet

FAA's CACI Weight Loss Management worksheet, updated 09/30/2026, lets an AME issue a certificate without sending the file to FAA when every item is met. It requires a clinical progress note from the treating physician within 90 days; a finding that the condition is stable with no medication side effects; no hypoglycemia of 70 mg/dL or less requiring intervention in the past 12 months; and no A1C of 6.5% or higher, ever. It also says "ONLY ONE of the medications listed is used," listing metformin, liraglutide, orforglipron (Foundayo), semaglutide (Wegovy, injection or oral), and tirzepatide (Zepbound). If any item is not met, the AME defers and submits documents to FAA.

Source: FAA, Weight Loss Pharmaceuticals (rev. 08/26/2026); FAA, CACI Weight Loss Management worksheet (updated 09/30/2026). The right-hand column is this guide's reading, not FAA text.

Where compounded GLP-1s fit: the honest answer is "not addressed"

Neither FAA document mentions compounded medications. That silence cuts both ways. It is not a statement that compounded semaglutide is acceptable, and it is not a statement that it is prohibited. The CACI worksheet lists products by brand name, so an AME may reasonably ask whether a compounded product is one of "the medications listed." Some AMEs may choose to defer to FAA rather than decide that question themselves. If anyone, including a telehealth service, tells you FAA has "approved" compounded GLP-1s for pilots, ask them to show you the FAA text.

Why a pharmacy switch can be a "formulation change"

Compounded GLP-1s are not standardized products. FDA's GLP-1 safety page (updated October 1, 2026) notes that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing, and that some hospitalizations may be linked to dosing errors. Different pharmacies may use different concentrations, vial sizes, and added ingredients.

Three practical consequences follow:

1. Concentration changes the math. If one vial holds 2.5 mg/mL and the next holds 5 mg/mL, the same number of syringe units delivers a different dose. A mistaken dose is a dose change whether or not you intended one.
2. Added ingredients change the product. Combinations such as semaglutide with vitamin B12 are a different formulation from plain semaglutide. FDA's April 1, 2026 compounding statement treats such combinations as their own products for compounding-law purposes.
3. Brand-to-compounded or compounded-to-brand switches are plausibly a "medication change" or "formulation change" under FAA's wording. FAA's guidance does not define those terms for this situation, so the conservative reading is to observe the 48-hour period and tell your AME.

Disclosing on MedXpress

FAA's guidance for Item 17.a of the medical application says applicants must report both prescription and nonprescription medications, giving the medication name and whether it was listed on a previous FAA exam. A compounded GLP-1 is a prescription medication. Report it, and be specific: active ingredient, any added ingredients, concentration, and dispensing pharmacy.

Documents worth keeping

• The prescription, including the prescriber's name and the exact formulation.
• The pharmacy label for each fill, showing concentration, beyond-use date, and pharmacy name and license.
• Your treating physician's progress notes and A1C results, since the CACI asks for a note within 90 days.
• A simple log of start dates, dose changes, product or pharmacy switches, and any side effects, so observation periods are easy to show.

Truck and bus drivers: what FMCSA rules say

FMCSA's physical qualification standards are at 49 CFR 391.41. They do not name GLP-1 medications. Two parts of the rule are relevant.

1. Diabetes. Section 391.41(b)(3) addresses a driver with "diabetes mellitus currently treated with insulin for control," who must meet the separate requirements of 391.46. It does not set a standard for diabetes managed without insulin or for weight-loss use.
2. Drugs. Section 391.41(b)(12) addresses Schedule I drugs, amphetamines, narcotics, other habit-forming drugs, and other federally scheduled substances unless prescribed by a practitioner who has advised the driver the substance will not adversely affect safe driving. The subsection does not name GLP-1 medications.

If a driver's diabetes is treated with insulin, 49 CFR 391.46 applies. The treating clinician completes the ITDM Assessment Form (MCSA-5870), the exam must occur no later than 45 days after the clinician signs it, and certification can last up to 12 months if the driver provides at least 3 months of electronic glucose monitoring records. A severe hypoglycemic episode, defined as one that "requires the assistance of others, or results in loss of consciousness, seizure, or coma," stops CMV driving until a clinician re-evaluates and completes a new form. A GLP-1 used alongside insulin does not change those insulin requirements.

Because the regulations do not address GLP-1s directly, how a particular driver's medication and side effects are weighed is left to the certified medical examiner. Tell the examiner about the medication, any other diabetes drugs, and any symptoms, and bring the same documentation a pilot would.

Worked example

A private pilot has been on brand Wegovy, meets the A1C criteria, and has an AME-issued certificate under the CACI. To save money, the pilot switches to compounded semaglutide from a telehealth service. Under FAA's wording, that switch is plausibly a medication or formulation change, so the conservative path is a 48-hour no-fly observation, documentation of the new product, and a call to the AME before the next exam. Because the CACI names brand products, the AME may decide to defer rather than issue on the spot. If the new vial's concentration differs from the instructions the pilot is used to, that is also the moment to confirm the dose in milligrams with the pharmacy.

Scenario guidance

• You are about to start a compounded GLP-1. Plan for the one-week observation, tell your AME, and keep pharmacy records from the first fill.
• Your pharmacy changed or your vial looks different. Confirm the concentration and dose in milligrams, then treat it as a possible formulation change.
• You are a CDL driver on a GLP-1 and insulin. The insulin rule at 391.46 governs; keep your MCSA-5870 and glucose records current.
• You are unsure how your AME will view a compounded product. Ask before your exam, not during it.

Questions to ask your AME, examiner, prescriber, or pharmacy

1. (AME) Will you consider a compounded GLP-1 as one of the medications listed on the CACI worksheet, or will you defer?
2. (AME) Do you treat a change of compounding pharmacy or concentration as a formulation change?
3. (Prescriber) Can your progress note identify the exact product, concentration, and pharmacy?
4. (Pharmacy) What is the concentration in mg/mL, are there added ingredients, and will that change between fills?
5. (FMCSA examiner) What documentation do you want for a GLP-1, and does my insulin use change anything?

Where this guide stops

This guide covers FAA examiner guidance and FMCSA regulations as published through October 19, 2026. It does not cover air traffic controllers, military aviation, airline company policies, union guidance, state intrastate driving rules, or drug-testing programs. FAA and FMCSA can update their guidance at any time, and your examiner's decision controls.

Compare available care options

If certification matters to your job, it may help to compare providers on what they will document: the exact product, the prescriber's license, and the dispensing pharmacy. A listing is not a recommendation or a prescription, and you should verify credentials and terms yourself.

Affiliate disclosure: this site may earn a commission if you use a listed provider. Compensation does not establish a provider's safety, legality, or value.

Sources

1. FAA Guide for Aviation Medical Examiners: Weight Loss Pharmaceuticals (revised 08/26/2026)
2. FAA: CACI Weight Loss Management worksheet (updated 09/30/2026)
3. FAA Guide for Aviation Medical Examiners: Item 17.a, Medications
4. 49 CFR 391.41, Physical qualifications for drivers (eCFR)
5. 49 CFR 391.46, Physical qualification standards for an individual with diabetes mellitus treated with insulin (eCFR)
6. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
7. FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.